Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution10.12.2025 - 2Kona SUV: The Courageous Minimized That is Catching Hearts Around the world06.11.2023
- 3Exploring ways to reduce the impact of space junk on Earth08.12.2025
- 4Find Successful Magnificence Items for Sparkling Skin06.06.2024
- 5Man triggers smoke bomb during failed crypto robbery25.11.2025
- Become the best at Discussion: 6 Procedures for Progress
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- Figure out How to Put resources into Lab Precious stones
- Famous Rough terrain Vehicles for 2024
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Texas cities have some of the highest preterm birth rates in the US, highlighting maternal health crisis nationwide
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
